Ga-68-Trivehexin靶向αvβ6整合素PET/CT成像头颈癌与胰腺癌
本研究开发了靶向αvβ6整合素的PET探针Ga-68-Trivehexin,通过ELISA和细胞结合实验表征其亲和力与选择性,并在小鼠模型中验证生物分布和PET成像,随后在头颈鳞癌、腮腺腺癌和转移性胰腺导管腺癌患者中进行PET/CT显像,显示肿瘤高摄取且能识别小转移灶。
要点
- Ga-68-Trivehexin对αvβ6整合素具有高亲和力(IC50=0.047 nM)和良好选择性。
- 临床PET/CT显示转移性胰腺癌和头颈鳞癌高摄取(SUVmax=10-13),可检出小转移灶。
- 肿瘤相关炎症未见高摄取,有助于鉴别肿瘤与炎症。
核心结论
- Ga-68-Trivehexin是靶向αvβ6整合素表达的人体癌症PET成像的有价值探针。
研究设计与样本
- 合成Ga-68-Trivehexin并通过ELISA和细胞结合实验表征,在荷瘤SCID小鼠中进行动态和静态µPET及生物分布研究,并在头颈鳞癌、腮腺腺癌和转移性胰腺导管腺癌患者中进行PET/CT显像。
主要发现
- Ga-68-Trivehexin对αvβ6整合素亲和力高(IC50=0.047 nM),选择性优于αvβ8(131倍)、αvβ3(57倍)和α5β1(468倍)。
- 临床PET/CT显示转移性胰腺导管腺癌和头颈鳞癌高且持续摄取(SUVmax=10-13),肾脏和尿液亦高摄取。
- Ga-68-Trivehexin可实现对小的胰腺癌转移灶的PET/CT成像,头颈鳞癌高摄取而肿瘤相关炎症无高摄取。
临床怎么用
- Ga-68-Trivehexin PET/CT可用于评估头颈癌和胰腺癌的αvβ6整合素表达,辅助检出小转移灶并鉴别肿瘤与炎症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To develop a new probe for the αvβ6-integrin and assess its potential for PET imaging of carcinomas. METHODS: Ga-68-Trivehexin was synthesized by trimerization of the optimized αvβ6-integrin selective cyclic nonapeptide Tyr2 (sequence: c[YRGDLAYp(NMe)K]) on the TRAP chelator core, followed by automated labeling with Ga-68. The tracer was characterized by ELISA for activities towards integrin subtypes αvβ6, αvβ8, αvβ3, and α5β1, as well as by cell binding assays on H2009 (αvβ6-positive) and MDA-MB-231 (αvβ6-negative) cells. SCID-mice bearing subcutaneous xenografts of the same cell lines were used for dynamic (90 min) and static (75 min p.i.) µPET imaging, as well as for biodistribution (90 min p.i.). Structure-activity-relationships were established by comparison with the predecessor compound Ga-68-TRAP(AvB6)3. Ga-68-Trivehexin was tested for in-human PET/CT imaging of HNSCC, parotideal adenocarcinoma, and metastatic PDAC. RESULTS: Ga-68-Trivehexin showed a high αvβ6-integrin affinity (IC50 = 0.047 nM), selectivity over other subtypes (IC50-based factors: αvβ8, 131; αvβ3, 57; α5β1, 468), blockable uptake in H2009 cells, and negligible uptake in MDA-MB-231 cells. Biodistribution and preclinical PET imaging confirmed a high target-specific uptake in tumor and a low non-specific uptake in other organs and tissues except the excretory organs (kidneys and urinary bladder). Preclinical PET corresponded well to in-human results, showing high and persistent uptake in metastatic PDAC and HNSCC (SUVmax = 10-13) as well as in kidneys/urine. Ga-68-Trivehexin enabled PET/CT imaging of small PDAC metastases and showed high uptake in HNSCC but not in tumor-associated inflammation. CONCLUSIONS: Ga-68-Trivehexin is a valuable probe for imaging of αvβ6-integrin expression in human cancers.
引用
- Quigley NG, Steiger K, Hoberück S, et al. PET/CT imaging of head-and-neck and pancreatic cancer in humans by targeting the "Cancer Integrin" αvβ6 with Ga-68-Trivehexin. Eur J Nucl Med Mol Imaging. 2021. PMID: 34559266. doi:10.1007/s00259-021-05559-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。